Ropivacaine 0.2% Injectable Solution for Cardiovascular Disease

Phase-Based Progress Estimates
University of Minnesota, Minneapolis, MNCardiovascular Disease+2 MoreRopivacaine 0.2% Injectable Solution - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing if a painkiller can also help prevent heart problems after surgery.

Eligible Conditions
  • Cardiovascular Disease
  • Local Anesthesia
  • Atrial Fibrillation

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 13 Secondary · Reporting Duration: 24, 48, 72, 96, and 120 hours post-operatively

Hour 72
Cumulative ICU sedation doses
Hour 120
Average pain score
Cumulative Opioid Use - Average Dosages
Cumulative Opioid Use - Morphine Equivalents
Quality of Recovery 15 (QOR-15) Scores
30 days
30-Day Mortality
5 days
Incidence of New-Onset Atrial Fibrillation (NOAF)
approximately 1 hour
Block performance time
approximately 24 hours
Duration of vasopressor requirement
approximately 5 days
Block-associated complications
Intensive Care Unit (ICU) Length of Stay
Time to Extubation
approximately 7 days
Diagnosis of delirium during index hospitalization
Hospital Length of Stay

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

1 of 2
1 of 2

Active Control

Experimental Treatment

30 Total Participants · 2 Treatment Groups

Primary Treatment: Ropivacaine 0.2% Injectable Solution · No Placebo Group · Phase 4

Experimental Group · 1 Intervention: Ropivacaine 0.2% Injectable Solution · Intervention Types: Drug
ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24, 48, 72, 96, and 120 hours post-operatively

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,271 Previous Clinical Trials
1,487,962 Total Patients Enrolled
James Flaherty, MDPrincipal InvestigatorUniversity of Minnesota
1 Previous Clinical Trials
77 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How many individuals have been enrolled in this experiment?

"Affirmative. According to the data accessible on, this medical trial is open for recruitment and has been since April 9th 2021. Its last update was February 25th 2022 and a total of 30 patients are needed from one single location." - Anonymous Online Contributor

Unverified Answer

What medical maladies is Ropivacaine 0.2% Injectable Solution typically utilized to address?

"Ropivacaine 0.2% Injectable Solution is a common anaesthetic medication typically used during surgical procedures and childbirth or to manage postoperative pain." - Anonymous Online Contributor

Unverified Answer

Are new participants being accepted at this point for the experiment?

"This is accurate; has reported that the trial, which was initially published on April 9th 2021, is actively recruiting to fill 30 vacancies across a solitary site of recruitment." - Anonymous Online Contributor

Unverified Answer

How hazardous is Ropivacaine 0.2% Injectable Solution to patients' wellbeing?

"There is an abundance of evidence supporting the safety of Ropivacaine 0.2% Injectable Solution, thus it's been awarded a 3 on our rating scale due to its Phase 4 status." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.